Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risdiplam safety, tolerability, PK/PD study in previously treated SMA patients
NL-OMON59243Phase 2Completed
- Sponsor
- Roche
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of risdiplam in spinal muscular atrophy (SMA), sponsored by Roche. Primary endpoints: Incidence and severity of adverse events and serious adverse events, Treatment discontinuations due to adverse events and 9 more. Started May 2019; status: completed.
02
Drugs
risdiplam
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NL-OMON59243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59243.